BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36185809)

  • 1. A novel membrane-bound interleukin-2 promotes NK-92 cell persistence and anti-tumor activity.
    Xiong Q; Zhang H; Ji X; Zhang Y; Shi G; Dai L; Cheng F; Wang H; Luo J; Xu J; Ji Y; Su X; Yang W; Zhang L; Deng H
    Oncoimmunology; 2022; 11(1):2127282. PubMed ID: 36185809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Membrane-bound interleukin (IL)-15 on renal tumor cells rescues natural killer cells from IL-2 starvation-induced apoptosis.
    Wittnebel S; Da Rocha S; Giron-Michel J; Jalil A; Opolon P; Escudier B; Validire P; Khawam K; Chouaib S; Azzarone B; Caignard A
    Cancer Res; 2007 Jun; 67(12):5594-9. PubMed ID: 17575122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
    Mani R; Rajgolikar G; Nunes J; Zapolnik K; Wasmuth R; Mo X; Byrd JC; Lee DA; Muthusamy N; Vasu S
    Cytotherapy; 2020 Jul; 22(7):369-376. PubMed ID: 32303428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21.
    Thangaraj JL; Phan MT; Kweon S; Kim J; Lee JM; Hwang I; Park J; Doh J; Lee SH; Vo MC; Chu TH; Song GY; Ahn SY; Jung SH; Kim HJ; Cho D; Lee JJ
    Cancer Immunol Immunother; 2022 Mar; 71(3):613-625. PubMed ID: 34282497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine engineered NK-92 therapy to improve persistence and anti-tumor activity.
    Shin HY; Jang S; Woo HJ; Chung JH; Kim WH; Kim D; Kang M; Lim Y; Habib O; Lee J; Yang S; Lee DH; Kim MS
    Theranostics; 2023; 13(5):1506-1519. PubMed ID: 37056568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine requirements for the growth and development of mouse NK cells in vitro.
    Toomey JA; Gays F; Foster D; Brooks CG
    J Leukoc Biol; 2003 Aug; 74(2):233-42. PubMed ID: 12885940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional NK cell repertoires are maintained through IL-2Rα and Fas ligand.
    Felices M; Lenvik TR; Ankarlo DE; Foley B; Curtsinger J; Luo X; Blazar BR; Anderson SK; Miller JS
    J Immunol; 2014 Apr; 192(8):3889-97. PubMed ID: 24634493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
    Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
    Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
    J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.
    Levitt LJ; Nagler A; Lee F; Abrams J; Shatsky M; Thompson D
    J Clin Invest; 1991 Jul; 88(1):67-75. PubMed ID: 1676038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15.
    Imamura M; Shook D; Kamiya T; Shimasaki N; Chai SM; Coustan-Smith E; Imai C; Campana D
    Blood; 2014 Aug; 124(7):1081-8. PubMed ID: 25006133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
    Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8+ T cells.
    Burgess SJ; Marusina AI; Pathmanathan I; Borrego F; Coligan JE
    J Immunol; 2006 Feb; 176(3):1490-7. PubMed ID: 16424177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy.
    Tam YK; Maki G; Miyagawa B; Hennemann B; Tonn T; Klingemann HG
    Hum Gene Ther; 1999 May; 10(8):1359-73. PubMed ID: 10365666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-18 synergism with interleukin-2 in cytotoxicity and NKG2D expression of human natural killer cells.
    Qi YY; Lu C; Ju Y; Wang ZE; Li YT; Shen YJ; Lu ZM
    Asian Pac J Cancer Prev; 2014; 15(18):7857-61. PubMed ID: 25292077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-2Rα up-regulation is mediated by latent membrane protein 1 and promotes lymphomagenesis and chemotherapy resistance in natural killer/T-cell lymphoma.
    Wang L; Bi XW; Zhu YJ; He YZ; Lai QY; Xia ZJ; Cai QQ
    Cancer Commun (Lond); 2018 Oct; 38(1):62. PubMed ID: 30340635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer.
    Rosen DB; Kvarnhammar AM; Laufer B; Knappe T; Karlsson JJ; Hong E; Lee YC; Thakar D; Zúñiga LA; Bang K; Sabharwal SS; Uppal K; Olling JD; Kjaergaard K; Kurpiers T; Schnabel M; Reich D; Glock P; Zettler J; Krusch M; Bernhard A; Heinig S; Konjik V; Wegge T; Hehn Y; Killian S; Viet L; Runz J; Faltinger F; Tabrizi M; Abel KL; Breinholt VM; Singel SM; Sprogøe K; Punnonen J
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35817480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suspension culture promoted the expansion of NK-92 cells ex vivo by enhancing the expression of IL-2 receptor.
    Huang H; Zhang S; Zhao Y; Xu R; Tan WS; Cai H
    Biotechnol J; 2024 Mar; 19(3):e2300654. PubMed ID: 38472089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro IL-2 or IFN-α-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients.
    Konjević G; Mirjačić Martinović K; Vuletić A; Babović N
    Melanoma Res; 2010 Dec; 20(6):459-67. PubMed ID: 20938360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells.
    Denman CJ; Senyukov VV; Somanchi SS; Phatarpekar PV; Kopp LM; Johnson JL; Singh H; Hurton L; Maiti SN; Huls MH; Champlin RE; Cooper LJ; Lee DA
    PLoS One; 2012; 7(1):e30264. PubMed ID: 22279576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.